Access to medicines, Sept. 29 -- Doctors Without Borders/Medecins Sans Frontieres (MSF) welcomes a newly announced agreement to expand access to a more affordable injectable version of pre-exposure prophylaxis (PrEP) for HIV prevention. The deal between the drug developer, Gilead Sciences, and two Indian generic manufacturers, Dr. Reddy's and Hetero, will make lenacapavir available to 120 countries and territories at a price of $40 per person per year starting in 2027.
However, the licensing agreement currently leaves out various low- and middle-income countries where approximately one quarter of new HIV infections occur.
HIV remains a key global public health challenge, with 1.3 million people becoming newly infected with HIV in 2023 a...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.